Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amag Pharmaceuticals (AMAG)

Amag Pharmaceuticals (AMAG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 362,266
  • Shares Outstanding, K 34,273
  • Annual Sales, $ 327,750 K
  • Annual Income, $ -466,460 K
  • 60-Month Beta 1.05
  • Price/Sales 1.11
  • Price/Cash Flow N/A
  • Price/Book 1.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate 0.09
  • Low Estimate -0.44
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +81.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.89 +33.97%
on 07/15/20
12.00 -11.92%
on 08/05/20
+2.87 (+37.27%)
since 07/14/20
3-Month
6.62 +59.67%
on 05/15/20
12.00 -11.92%
on 08/05/20
+3.84 (+57.06%)
since 05/14/20
52-Week
4.41 +139.68%
on 03/18/20
13.53 -21.88%
on 10/28/19
-1.59 (-13.08%)
since 08/14/19

Most Recent Stories

More News
Thinking about buying stock in AMAG Pharmaceuticals, Trevena Inc, Energous Corp, Catalyst Pharmaceuticals, or Plug Power?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMAG, TRVN, WATT, CPRX, and PLUG.

AMAG : 10.57 (unch)
CPRX : 3.47 (+1.76%)
WATT : 3.30 (-2.08%)
TRVN : 2.33 (-1.69%)
Amag Pharmaceuti Shares Up 27.1% Since SmarTrend's Buy Recommendation (AMAG)

SmarTrend identified an Uptrend for Amag Pharmaceuti (NASDAQ:AMAG) on July 16th, 2020 at $8.51. In approximately 4 weeks, Amag Pharmaceuti has returned 27.10% as of today's recent price of $10.81.

AMAG : 10.57 (unch)
AMAG Pharmaceuticals (AMAG) Moves to Buy: Rationale Behind the Upgrade

AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AMAG : 10.57 (unch)
AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

AMAG : 10.57 (unch)
EBS : 133.42 (-1.13%)
ALIM : 6.09 (-5.14%)
ACIU : 6.86 (-1.44%)
AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Lags Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AMAG : 10.57 (unch)
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Financial guidance reissued to include EBITDA-positive projection for second-half 2020

AMAG : 10.57 (unch)
AMAG Pharmaceuticals to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S. financial markets open. Management...

AMAG : 10.57 (unch)
AMAG Pharmaceuticals Completes Divestment of Women's Health Assets

Vyleesi(R) returned to Palatin Technologies

PTN : 0.5650 (+5.73%)
AMAG : 10.57 (unch)
Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®

, /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin...

AMAG : 10.57 (unch)
PTN : 0.5650 (+5.73%)
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties

AMAG : 10.57 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade AMAG with:

Business Summary

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the...

See More

Key Turning Points

2nd Resistance Point 10.89
1st Resistance Point 10.73
Last Price 10.57
1st Support Level 10.37
2nd Support Level 10.17

See More

52-Week High 13.53
Last Price 10.57
Fibonacci 61.8% 10.05
Fibonacci 50% 8.97
Fibonacci 38.2% 7.89
52-Week Low 4.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar